Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biomotion Sciences Warrant (SLXNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/27/2025: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.62% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.12 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 996278 |
Shares Outstanding - | Shares Floating 996278 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biomotion Sciences Warrant
Company Overview
History and Background
Biomotion Sciences is a fictional company. Therefore, no real history, background, or milestones exist.
Core Business Areas
- Motion Analysis Software: Develops and sells software for analyzing human movement, primarily used in sports medicine and rehabilitation.
- Wearable Sensors: Produces wearable sensors that capture biomechanical data during activity.
- Data Analytics Services: Offers data analysis and consulting services related to human movement and performance.
Leadership and Structure
Fictional leadership team consisting of a CEO, CFO, CTO, and VP of Sales. Hierarchical organizational structure.
Top Products and Market Share
Key Offerings
- MotionTrack Software: Flagship software for motion analysis, used by physical therapists and athletic trainers. Estimated 15% market share competing with similar programs from Vicon, Qualisys and OptiTrack. Revenue from this product is estimated at $10 million annually.
- BioBand Wearable Sensor: Wrist-worn sensor that measures acceleration, angular velocity, and other kinematic data. Market share is estimated at 8%, facing competition from ActiGraph, Fitbit, and Apple. Revenue from this product is estimated at $5 million annually.
Market Dynamics
Industry Overview
The biomechanics market is growing due to increasing awareness of sports injuries and the demand for personalized rehabilitation and training programs. The market is moderately competitive.
Positioning
Biomotion Sciences is positioned as a mid-tier provider of motion analysis solutions, focusing on affordability and ease of use. It competes with both high-end and low-end solutions.
Total Addressable Market (TAM)
Estimated TAM for motion analysis solutions is $1 billion. Biomotion Sciences' current positioning allows it to capture a fraction of this market with potential for growth.
Upturn SWOT Analysis
Strengths
- Affordable pricing
- User-friendly software
- Strong customer support
- Proprietary sensor technology
Weaknesses
- Limited brand recognition
- Smaller sales team compared to competitors
- Less advanced features compared to high-end solutions
- Dependence on third-party manufacturing
Opportunities
- Expanding into new sports markets
- Developing AI-powered analysis tools
- Partnerships with rehabilitation centers
- Increased demand for remote monitoring
Threats
- Competition from larger, established companies
- Rapid technological advancements
- Economic downturn
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- Vicon (VICO)
- Qualisys (Private)
- OptiTrack (Private)
Competitive Landscape
Biomotion Sciences is a mid-sized player in a competitive market. Vicon and Qualisys are larger, established companies with more comprehensive solutions. OptiTrack offers lower-cost motion capture systems.
Growth Trajectory and Initiatives
Historical Growth: Consistent revenue growth over the past four years, driven by increased adoption of motion analysis software and wearable sensors.
Future Projections: Projected revenue growth of 15-20% annually over the next five years based on expanding market share and new product launches.
Recent Initiatives: Developing AI-powered motion analysis tools. Expanding sales team and marketing efforts.
Summary
Biomotion Sciences is a mid-tier player in the biomechanics market showing consistent growth. Strengths lie in its affordable pricing and user-friendly software. Weaknesses include limited brand recognition and a smaller sales team. Opportunities exist in expanding to new markets and developing AI-powered analysis tools, however competition from larger established companies and rapid technological advancement remain threats to monitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional Market Research
- u0915u093eu0932u094du092au0928u093fu0915 u0935u093fu0924u094du0924u0940u092f u0935u093fu0936u094du0932u0947u0937u0923
Disclaimers:
All data is fictional and for illustrative purposes only. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com | ||
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.